KRAS and breast neoplasm: Furthermore, target inhibition does not necessarily correlate directly with efficacy, and O'Brien and colleagues have demonstrated that there was no marked tumour growth inhibition of KRAS mutant MDA-MB-231 breast tumour xenografts despite pronounced inhibition of AKT phosphorylation [5].